Initial trends in the use of the 21-gene recurrence score assay for patients with breast cancer in the medicare population, 2005-2009

JAMA Oncology

Volumn 1, Issue 2, 2015, Pages 158-166

  Dinan, Michaela A ^a,b,c   Mi, Xiaojuan ^a   Reed, Shelby D ^a,b,c   Hirsch, Bradford R ^a,b,c   Lyman, Gary H ^d,e   Curtis, Lesley H ^a,c  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d USA   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; AGE; AGED; ANCESTRY GROUP; BREAST NEOPLASMS; CANCER REGISTRY; CANCER STAGING; CHI SQUARE DISTRIBUTION; CLINICAL PRACTICE; DEMOGRAPHY; EPIDEMIOLOGY; ETHNOLOGY; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; HEALTH CARE DISPARITY; HUMAN; MEDICARE; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOLOGY; PHENOTYPE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROCEDURES; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; TRENDS; TUMOR RECURRENCE; UNITED STATES; UTILIZATION; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; CONTINENTAL POPULATION GROUPS; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GUIDELINE ADHERENCE; HEALTHCARE DISPARITIES; HUMANS; MEDICARE; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; PHENOTYPE; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PREDICTIVE VALUE OF TESTS; RESIDENCE CHARACTERISTICS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84965090578     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.43     Document Type: Article

References (28)

1. Peto R, Davies C, Godwin J, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432-444.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
3. National Comprehensive Cancer Network. NCCN guidelines for treatment of cancer by site: breast, version 3 [registration required]. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#breast.Accessed June 29, 2013.
4. Ademuyiwa FO, Miller A, O'Connor T, et al. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat. 2011;126(3):797-802.
5. Rouzier R, Pronzato P, Chéreau E, Carlson J, Hunt B, Valentine WJ. Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast Cancer Res Treat. 2013;139(3):621-637.
6. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826.
7. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734.
8. Harris L, Fritsche H, Mennel R, et al; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-5312.
9. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-1747.
10. Health Net. National Medical Policy: Oncotype DX for Cancer. https://www.healthnet.com/static/general/unprotected/pdfs/national/policies/OncotypeDXforCancer.pdf.Accessed September 3, 2013.
11. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8)(suppl):IV-3-IV-18.
12. Giordano SH, Lin YL, Kuo YF, Hortobagyi GN, Goodwin JS. Decline in the use of anthracyclines for breast cancer. J Clin Oncol. 2012;30(18):2232-2239.
13. Dinan MA, Curtis LH, Hammill BG, et al. Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA. 2010;303(16):1625-1631.
14. Dinan MA, Curtis LH, Carpenter WR, et al. Variations in use of PET among Medicare beneficiaries with non-small cell lung cancer, 1998-2007. Radiology. 2013;267(3):807-817.
15. Dinan MA, Curtis LH, Carpenter WR, et al. Redistribution of health care costs after the adoption of positron emission tomography among Medicare beneficiaries with non-small-cell lung cancer, 1998-2005. J Thorac Oncol. 2014;9(4):512-518.
16. Albain KS, Barlow WE, Shak S, et al; Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65.
17. Eiermann W, Rezai M, Kümmel S, et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol. 2013;24(3):618-624.
18. Parker L, Levin DC, Frangos A, Rao VM. Geographic variation in the utilization of noninvasive diagnostic imaging: national Medicare data, 1998-2007. AJR Am J Roentgenol. 2010;194(4):1034-1039.
19. Berwick DM. Disseminating innovations in health care. JAMA. 2003;289(15):1969-1975.
20. Groeneveld PW, Laufer SB, Garber AM. Technology diffusion, hospital variation, and racial disparities among elderly Medicare beneficiaries: 1989-2000. Med Care. 2005;43(4):320-329.
21. Department of Health & Human Services, Center for Medicare and & Medicaid Services. CMS manual system: Pub 100-03 Medicare national coverage determinations: transmittal 31: pet for brain, cervical, ovarian, pancreatic, small cell lung, and testicular cancers [2005]. http://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R31NCD.pdf. Accessed July 20, 2009.
22. Mitchell JM. Utilization trends for advanced imaging procedures: evidence from individuals with private insurance coverage in California. Med Care. 2008;46(5):460-466.
23. Mitchell JM. Urologists' use of intensity-modulated radiation therapy for prostate cancer. N Engl J Med. 2013;369(17):1629-1637.
24. Hassett MJ, Silver SM, Hughes ME, et al. Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol. 2012;30(18):2218-2226.
25. Davidson JA, Cromwell I, Ellard SL, et al. A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer. Eur J Cancer. 2013;49(11):2469-2475.
26. Markopoulos C, Xepapadakis G, Venizelos V, et al. Clinical experience of using Oncotype DX as an additional treatment decision tool in early breast cancer-aretrospective analysis from 5 Greek institutions. Eur J Surg Oncol. 2012;38(5):413-419.
27. Geffen DB, Abu-Ghanem S, Sion-Vardy N, et al. The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy. Ann Oncol. 2011;22(11):2381-2386.
28. Hornberger J, Chien R, Krebs K, Hochheiser L. US insurance program's experience with a multigene assay for early-stage breast cancer. Am J Manag Care. 2011;17(5 spec No):e194-e202.